ECSP034453A - Acoplamiento eficiente de ullman ligando-acelerada de anilinas y azoles - Google Patents

Acoplamiento eficiente de ullman ligando-acelerada de anilinas y azoles

Info

Publication number
ECSP034453A
ECSP034453A EC2003004453A ECSP034453A ECSP034453A EC SP034453 A ECSP034453 A EC SP034453A EC 2003004453 A EC2003004453 A EC 2003004453A EC SP034453 A ECSP034453 A EC SP034453A EC SP034453 A ECSP034453 A EC SP034453A
Authority
EC
Ecuador
Prior art keywords
azoles
ullman
accelerated
anilinas
binding
Prior art date
Application number
EC2003004453A
Other languages
English (en)
Inventor
Hui Yin Li
Jia Cheng Zhou
Lucius T Rossano
Christopher A Teleha
Pasquale N Confalone
Charles G Clark
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of ECSP034453A publication Critical patent/ECSP034453A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C07D233/38—One oxygen atom with acyl radicals or hetero atoms directly attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Executing Machine-Instructions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención provee un método para la preparación de azoles fenil sustituidos. Este método emplea una eficiente reacción de acoplamiento Ullman ligando-acelerada de anilinas con azoles. Los productos de acoplamiento son útiles para preparar los inhibidores del factor Xa.
EC2003004453A 2000-07-26 2003-01-24 Acoplamiento eficiente de ullman ligando-acelerada de anilinas y azoles ECSP034453A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22093200P 2000-07-26 2000-07-26

Publications (1)

Publication Number Publication Date
ECSP034453A true ECSP034453A (es) 2003-03-31

Family

ID=22825611

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004453A ECSP034453A (es) 2000-07-26 2003-01-24 Acoplamiento eficiente de ullman ligando-acelerada de anilinas y azoles

Country Status (22)

Country Link
US (1) US6541639B2 (es)
EP (1) EP1307431B1 (es)
JP (1) JP2004504384A (es)
KR (1) KR20030060872A (es)
CN (1) CN1444565A (es)
AT (1) ATE307804T1 (es)
AU (1) AU2001280813A1 (es)
BR (1) BR0112746A (es)
CA (1) CA2417426A1 (es)
DE (1) DE60114424T2 (es)
EC (1) ECSP034453A (es)
ES (1) ES2251501T3 (es)
HU (1) HUP0301699A3 (es)
IL (1) IL153547A0 (es)
IS (1) IS6695A (es)
MX (1) MXPA03000686A (es)
NO (1) NO20030393L (es)
NZ (1) NZ523271A (es)
PL (1) PL361233A1 (es)
RU (1) RU2003103706A (es)
WO (1) WO2002008199A2 (es)
ZA (1) ZA200300039B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050026811A1 (en) * 2003-05-20 2005-02-03 Mjalli Adnan M. M. Rage antagonists as agents to reverse amyloidosis and diseases associated therewith
DK2272813T3 (en) * 2001-04-24 2017-02-27 Massachusetts Inst Of Tech (Mit) COPPER CATALYST CREATION OF CARBON OXYGEN COMPOUNDS
EP2324830A1 (en) * 2002-03-05 2011-05-25 TransTech Pharma Inc. Process for the preparation of a monocyclic azole derivative that inhibits the interaction of ligands with rage
JP2006501159A (ja) * 2002-05-31 2006-01-12 ロデイア・シミ 炭素−炭素結合又は炭素−ヘテロ原子結合の形成方法
WO2004013094A2 (en) 2002-08-02 2004-02-12 Massachusetts Institute Of Technology Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds
AU2003270861A1 (en) * 2002-10-02 2004-04-23 Bristol-Myers Squibb Company Novel combination of a factor xa inhibitor and clopidogrel
WO2006009431A1 (en) * 2004-07-16 2006-01-26 Dsm Ip Assets B.V. Process for the preparation of an (hetero)arylamine
KR101999300B1 (ko) 2007-03-12 2019-07-12 인트라-셀룰라 써래피스, 인코퍼레이티드. 치환된 헤테로환 융합 감마-카르볼린 합성
WO2011041198A1 (en) 2009-09-30 2011-04-07 Transtech Pharma, Inc. Substituted imidazole derivatives for treatment of alzheimers disease
CA2870303A1 (en) 2012-04-14 2013-10-17 Intra-Cellular Therapies, Inc. Organic compounds
HUE053159T2 (hu) 2013-03-15 2021-06-28 Intra Cellular Therapies Inc Szerves vegyületek
IL246002B2 (en) 2013-12-03 2024-11-01 Intra Cellular Therapies Inc Converted compounds of gamma-carboline fused with heterocycles for use in the treatment of residual symptoms of psychosis and a long-acting injectable preparation containing these compounds in a matrix
JP2017509677A (ja) 2014-04-04 2017-04-06 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
KR20220054908A (ko) 2014-04-04 2022-05-03 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
WO2015171951A1 (en) * 2014-05-07 2015-11-12 The Regents Of The University Of Colorado, A Body Corporate 2-(4-aryl-1h-imidazol-1-yl)aniline compounds
IL318649A (en) 2016-01-26 2025-03-01 Intra Cellular Therapies Inc Organic compounds
BR112018069594B1 (pt) 2016-03-25 2023-12-05 Intra-Cellular Therapies, Inc Compostos orgânicos, composição farmacêutica compreendendo os ditos compostos e uso dos mesmos para o tratamento ou profilaxia de um distúrbio do sistema nervoso central
WO2017172795A1 (en) 2016-03-28 2017-10-05 Intra-Cellular Therapies, Inc. Novel compositions and methods
US11014925B2 (en) 2016-03-28 2021-05-25 Intra-Cellular Therapies, Inc. Co-crystals of 1-(4-fluoro-phenyl)-4-((6bR,1OaS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H- pyrido[3′,4′:4,51_pyrrolo [1,2,3-delqcuinoxalin-8-yl)-butan-1-one with nicotinamide or isonicotinamide
JP2019513143A (ja) 2016-03-28 2019-05-23 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規塩類および結晶
WO2018071233A1 (en) 2016-10-12 2018-04-19 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
EP3562484B1 (en) 2016-12-29 2021-08-25 Intra-Cellular Therapies, Inc. Pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline derivatives useful in the treatment of cns disorders
WO2018126140A1 (en) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
IL304026B2 (en) 2017-03-24 2024-11-01 Intra Cellular Therapies Inc A pharmaceutical preparation containing 1-(4-fluoro-phenyl)-4-((Sa10,Rb6)-3-D2-2,2-methyl-2, 3, a10, 10, 9, b6- hexahydro-H7, H1- Pyrido[3',4',:4,5]pyrrolo[3,2,1-de]quioxalin-8-yl)-butan-1-one and its uses
IL272252B2 (en) 2017-07-26 2024-03-01 Intra Cellular Therapies Inc Derivatives of substituted heterocycle fused gamma-carbolines, pharmaceutical compositions comnprising them and their use in treatment
MX2020000968A (es) 2017-07-26 2020-09-28 Intra Cellular Therapies Inc Compuestos organicos.
SMT202200134T1 (it) 2018-03-08 2022-05-12 Incyte Corp Composti di amminopirazindiolo come inibitori di pi3k-y
WO2019183341A1 (en) 2018-03-23 2019-09-26 Intra-Cellular Therapies, Inc. Organic compounds
JP7476115B2 (ja) 2018-06-06 2024-04-30 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規の塩および結晶
MX2020013335A (es) 2018-06-08 2021-05-27 Intra Cellular Therapies Inc Metodos novedosos.
CA3240552A1 (en) 2018-06-11 2019-12-19 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines synthesis
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
US12144808B2 (en) 2018-08-29 2024-11-19 Intra-Cellular Therapies, Inc. Compositions and methods
BR112021003838A2 (pt) 2018-08-31 2021-05-18 Intra-Cellular Therapies, Inc. métodos novos
MX2021002322A (es) 2018-08-31 2021-04-28 Intra Cellular Therapies Inc Nuevos metodos.
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
US12297200B2 (en) 2018-12-17 2025-05-13 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines synthesis
IL315005B1 (en) 2018-12-17 2025-12-01 Intra Cellular Therapies Inc Substituted heterocycle fused gamma-carbolines synthesis
MX2022000143A (es) 2019-07-07 2022-02-17 Intra Cellular Therapies Inc Metodos novedosos.
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6372658A (ja) 1986-09-17 1988-04-02 Sumitomo Chem Co Ltd ニトロジフエニルアミン類の製造方法
US5705697A (en) 1997-01-30 1998-01-06 Xerox Corporation Arylamine processes
ZA985247B (en) 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.

Also Published As

Publication number Publication date
BR0112746A (pt) 2003-09-09
DE60114424T2 (de) 2006-07-27
KR20030060872A (ko) 2003-07-16
ATE307804T1 (de) 2005-11-15
DE60114424D1 (de) 2005-12-01
HUP0301699A3 (en) 2004-03-29
US20020099225A1 (en) 2002-07-25
HUP0301699A2 (hu) 2003-12-29
WO2002008199A3 (en) 2002-06-13
IS6695A (is) 2003-01-22
NZ523271A (en) 2005-01-28
EP1307431B1 (en) 2005-10-26
JP2004504384A (ja) 2004-02-12
AU2001280813A1 (en) 2002-02-05
MXPA03000686A (es) 2003-06-06
EP1307431A2 (en) 2003-05-07
RU2003103706A (ru) 2004-08-10
CN1444565A (zh) 2003-09-24
IL153547A0 (en) 2003-07-06
CA2417426A1 (en) 2002-01-31
PL361233A1 (en) 2004-10-04
ES2251501T3 (es) 2006-05-01
ZA200300039B (en) 2004-04-02
WO2002008199A2 (en) 2002-01-31
NO20030393D0 (no) 2003-01-24
NO20030393L (no) 2003-03-24
US6541639B2 (en) 2003-04-01

Similar Documents

Publication Publication Date Title
ECSP034453A (es) Acoplamiento eficiente de ullman ligando-acelerada de anilinas y azoles
CY1109276T1 (el) Φωσφονοκεφεμικα παραγωγα, διαδικασια για την παρασκευη τους, και χρηση αυτων
DOP2011000301A (es) Derivados de azaadamantano y metodos de uso de los mismos
ES2207298T3 (es) Nuevos esteres derivados de compuestos fenil-ciclohexil substituidos.
AR019507A1 (es) Uso de los inhibidores de cyp2d6 en terapias de combinacion
ES2136037B1 (es) Inhibidores de sulfamida-metaloproteasa
EA200001129A3 (ru) Способ получения 4-карбоксиамино-2-замещенного-1,2,3,4-тетрагидрохинолина
DE60112093D1 (de) Splittersicherung für leuchtstofflampen
NO20025590D0 (no) Fenylglycin-derivater
ATE359431T1 (de) Vorrichtung und verfahren zur elektrischen kupplung
ITTO20020349A1 (it) Apparecchiatura di avviamento del motore.
UY26675A1 (es) Sales de imidazo-3-aminas e imidazo-5-aminas bicíclicas n-aciladas y sus productos de adicción con ácidos, procedimientos para su preparación y medicamentos que contienen estos compuestos
DE60105025D1 (de) Pharmazeutische verbindungen zur behandlung von chronisch-obstruktiver bronchopneumonie
SI1325022T1 (sl) Metoda za pripravo 21-hidroksi-6,19-oksidoprogesterona (21oh-6op)
NO20032241D0 (no) Forbedret prosess for vannlöselige azolforbindelser
BR0212153A (pt) Compostos e respectivos processos de preparação e de isolamento de dicloreto de 2-difluormetilornitina
IS2273B (is) Aðferð fyrir nýsmíðina á HIV próteasa lötum
NO20032558D0 (no) Fremgangsmåte for fremstilling av paklitaxel
DE60124148D1 (de) Kalzilytische verbindungen
ATE376382T1 (de) Kabeltrommel
IT1307355B1 (it) Apparato per la generazione di una frequenza di riferimento.
IT1319660B1 (it) Processo per la preparazione di 1-(1-amminoalchil)ossirani protetti.
CR5714A (es) Compuesto insecticidas de oxadiacina
DE60108515D1 (de) Verfahren zur herstellung eines pgd2-antagonisten
ATE288779T1 (de) Nicht-antibakterielle tetrazykline als anti-pilz medikamente